Description de l'entreprise
Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers Evrenzo, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf and Advagraf/Graceptor/ASTAGRAF XL immunosuppressants.
Conseil d'administration & Conseil de surveillance
| PDG |
| Naoki Okamura |
| Conseil d'administration |
| Atsushi Kitamura, Katsuyoshi Sugita, Yoshitsugu Shitaka, Tadaaki Taniguchi, Hideki Shima, Claus Zieler, Adam Pearson, Catherine Levitt |
| Conseil de surveillance |
| Kenji Yasukawa, Naoki Okamura, Katsuyoshi Sugita, Takashi Tanaka, Eriko Sakurai, Masahiro Miyazaki, Yoichi Ohno, Toru Yoshimitsu, Raita Takahashi, Mika Nakayama, Rie Akiyama |
Données de l'entreprise
| Nom: |
Astellas Pharma Inc. |
| Adresse: |
2-5-1, Nihonbashi-Honcho,Chuo-Ku, Tokyo 103-8411 |
| Téléphone: |
+81-3-3244-3000 |
| Fax: |
- |
| Courriel: |
-
|
| Internet: |
https://www.astellas.com/en/ |
| Industrie: |
Healthcare |
| Secteur: |
Pharmaceutical Industry |
| Sous-secteur: |
- |
| Fin de l'exercice financier: |
31/03 |
| Flotte libre: |
- |
| IPO date: |
- |
Relations avec les investisseurs
| Nom: |
- |
| Téléphone IR: |
+81-3-3244-3202 |
| IR-Fax: |
- |
| E-mail IR: |
-
|
